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Mutations in human MPV17 cause a hepatocerebral 
form of mitochondrial DNA depletion syndrome (MDS) 
hallmarked by early-onset liver failure, leading to pre-
mature death. Liver transplantation and frequent feed-
ing using slow-release carbohydrates are the only 
available therapies, although surviving patients eventu-
ally develop slowly progressive peripheral and central 
neuropathy. The physiological role of Mpv17, includ-
ing its functional link to mitochondrial DNA (mtDNA) 
maintenance, is still unclear. We show here that Mpv17 
is part of a high molecular weight complex of unknown 
composition, which is essential for mtDNA maintenance 
in critical tissues, i.e. liver, of a Mpv17 knockout mouse 
model. On a standard diet, Mpv17−/− mouse shows 
hardly any symptom of liver dysfunction, but a keto-
genic diet (KD) leads these animals to liver cirrhosis and 
failure.  However, when expression of human MPV17 is 
carried out by adeno-associated virus (AAV)-mediated 
gene  replacement, the Mpv17 knockout mice are able 
to reconstitute the Mpv17-containing supramolecu-
lar complex, restore liver mtDNA copy number and 
 oxidative phosphorylation (OXPHOS) proficiency, and 
prevent liver failure induced by the KD. These results 
open new therapeutic perspectives for the treatment of 
MPV17-related liver-specific MDS.
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INTRODUCTION
The term mitochondrial DNA depletion syndrome (MDS) indi-
cates a heterogeneous group of diseases characterized by pro-
found reduction in mitochondrial DNA (mtDNA) copy number 
in one or several tissues.1 Myopathic, encephalomyopathic, and 
hepatocerebral forms of MDS are known, due to mutations in 
gene products involved in mtDNA maintenance, either by con-
trolling the supply of deoxynucleotides for, or by carrying out, the 
synthesis of mtDNA. MDS is considered rare, with an estimated 
prevalence of 1:100,000,2 although the number of genes associated 
with this condition is rapidly expanding, and a systematic diag-
nostic screening is hampered by tissue specificity. For instance, 
thymidine kinase 23 and guanosine kinase4 are the two enzymes 
involved in deoxynucleotide recycling in mitochondria; p53-ribo-
nucleotide reductase subunit 25 and thymidine phosphorylase6 are 
the two cytosolic enzymes controlling the de novo biosynthesis of 
deoxynucleotides (p53-ribonucleotide reductase subunit 2) and 
the catabolism of nucleotides (thymidine phosphorylase), respec-
tively; polymerase γ7 is the mitochondrion-specific DNA poly-
merase and Twinkle,8 the mtDNA helicase. MPV179–16, a small 
protein of the inner mitochondrial membrane, is a prominent 
cause of hepatocerebral MDS, accounting for about 50% of the 
cases. More than 20 different MPV17 mutations in >70 patients 
have been reported so far. However, the functional and mechanis-
tic links between Mpv17 and mtDNA maintenance are still miss-
ing. Nevertheless, studies on SYM1, the MPV17 yeast ortholog, 
suggest a role for this protein in controlling the flux of Krebs cycle 
intermediates across the inner mitochondrial membrane. How 
this functional data relate to mtDNA maintenance and integrity 
are unknown. In addition, studies based on blue native gel elec-
trophoresis have demonstrated that SYM1 is present within a high 
molecular weight complex of ~600 kDa, the composition of which 
is, however, unknown.17
Liver involvement associated with severe hypoglycemic cri-
ses and rapidly progressive deterioration of hepatic function, 
leading to liver cirrhosis and failure, are early and predominant 
features of MPV17-dependent MDS. Unlike other MDS, neuro-
logical involvement in MPV17-associated hepatocerebral MDS is 
generally mild or absent at disease onset, but progressive periph-
eral neuropathy and cerebellar degeneration appear later in those 
MPV17 mutant patients who survive fatal, early-onset metabolic 
impairment, and liver failure. Although no cure is currently avail-
able for MPV17-related MDS, therapeutic interventions based 
on liver transplantation13,14 or on frequent meals of a cornstarch-
based diet18 have been attempted, to delay disease progression or 
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protect patients from fatal hypoglycemia. Liver transplantation 
has been carried out in 10 patients but five of them died early 
thereafter of multiorgan failure or sepsis.14 Prompt-release carbo-
hydrates, such as cornstarch, seem to be effective in preventing 
fatal hypoglycemic accidents, but the surviving patients invari-
ably progress to hepatic, and eventually neurological, degenera-
tion. Central and peripheral neuropathy is a predominant feature 
in subjects affected by Navajo neurohepatopathy, a well-known 
disease of Navajo people from south-east US, recently shown to 
be caused by a specific mutation in the MPV17 gene.19 Clinical 
features of Navajo neurohepatopathy/MPV17 syndrome include 
sensory motor neuropathy with ataxia, leukoencephalopathy, cor-
neal ulcerations, acral mutilation, poor somatic development with 
sexual infantilism, serious systemic infections, and, of course, 
liver derangement.
The knockout mouse for Mpv17 (Mpv17−/−) is characterized by 
profound, early-onset mtDNA depletion in liver,10 degeneration 
of the inner ear structures, particularly of the organ of Corti and 
stria vascularis, determining profound hearing loss,20 and late-
onset, fatal kidney dysfunction, dominated by proteinuria due to 
focal segmental glomerulosclerosis.10 Although the molecular and 
biochemical features in the liver of Mpv17−/− mice closely resem-
ble those of human patients, including severe mtDNA depletion, 
these animals show hardly any sign of hepatic dysfunction in 
standard captivity conditions and live well beyond the first year 
of life, with neither obvious neurological impairment nor neuro-
pathological abnormalities. However, we show here that Mpv17−/− 
mice fed with a high-fat ketogenic diet (KD) rapidly develop liver 
cirrhosis and failure. Importantly, treatment with a liver-specific 
adenoassociated viral vector (serotype 2/8, AAV2/8) expressing 
human MPV17 (hMPV17) restores mtDNA copy number and 
prevents liver degeneration. This effect is linked to the formation 
of the 600 kDa complex containing Mpv17, since Mpv17 variants 
that do not allow this structure to be formed cannot rescue the 
liver phenotype in vivo.
RESULTS
Mpv17 is part of a high molecular weight complex
In order to investigate the physical status of Mpv17 in vivo, we 
analyzed isolated mitochondria from Mpv17+/− and Mpv17−/− liv-
ers by 2-dimensional blue native gel electrophoresis (2D-BNGE) 
immunoblot, using an antibody specific against the mammalian 
Mpv17 protein (αMpv17). Although the antibody did not work 
in the (native) first dimension, in the (denaturing) second dimen-
sion, the αMpv17 was able to visualize Mpv17 crossreacting mate-
rial in the mitochondria of control, but not of knockout mice. 
Most of the 20 kDa Mpv17 protein was in fact present in a spot 
corresponding to a complex of >600 kDa, as suggested by restain-
ing with an αCore1 antibody marking the mitochondrial complex 
III dimer (Figure 1). These findings are identical to those previ-
ously obtained on SYM1.17
AAV2/8-mediated hMPV17 expression rescue the 
Mpv17−/− mouse liver phenotype
We constructed an AAV2/8 viral vector expressing the hMPV17 
cDNA to the liver, under the control of the liver-specific thyroxine-
binding globulin (TBG) promoter. The hMPV17 protein is almost 
identical to the mouse (m)Mpv17 protein, displaying 14 changes, 
none of which was in highly conserved residues or was predicted 
to have deleterious consequences by SIFT analysis (Supplementary 
Figure S1).21 AAV2/8-hMPV17 was administered to groups of 
2-month-old Mpv17−/− and Mpv17+/− mice (n = 4 each) by retroor-
bital injection at a concentration of 4 × 1012 viral genomes (vg)/kg. 
The mice were sacrificed 3 weeks later. Blood samples drawn before 
AAV treatment and again just before the sacrifice showed that aspar-
tate aminotransferase and alanine aminotransferase enzymes, two 
markers of hepatocyte leakage, were high before AAV administra-
tion in Mpv17−/− mice, whereas they were normalized after AAV 
administration (Figure 2a), suggesting correction of liver damage. 
No change was observed in control animals upon AAV injection, 
suggesting that AAV has no hepatotoxicity per se. Viral DNA was 
detected by polymerase chain reaction (PCR) in liver, but not in 
kidney, skeletal muscle, heart, and brain (data not shown), confirm-
ing the specific hepatotropism of AAV2/822; similar amounts of viral 
DNA per cell were found in Mpv17+/− and Mpv17−/− livers (0.9 ± 0.3 
versus 1.2 ± 0.5; Figure 2b). Next, we measured MPV17 mRNA 
expression by real-time (RT)-qPCR. Since human and mouse 
MPV17 sequences are almost identical, we were unable to design 
primers suitable to distinguish endogenous from AAV-mediated 
expression. However, in both AAV-treated Mpv17−/− and Mpv17+/− 
mice, Mpv17 mRNA levels were much higher than the levels found 
in untreated Mpv17+/− mice (Figure 2f). Accordingly, western 
blot immunovisualization with αMpv17 showed that the amount 
of Mpv17-crossreacting material in AAV-treated Mpv17−/− liver 
homogenates (data not shown) and isolated mitochondria (Figure 
2d) were much higher than that found in control mice. Analysis by 
2D-BNGE immunoblotting demonstrated that hMPV17 was inte-
grated into a high molecular weight complex similar to that detected 
in control mitochondria (Figure 2e). The mtDNA copy number 
was markedly increased in livers from AAV-treated Mpv17−/− mice 
(1282 ± 372 copies/cell) compared to untreated Mpv17−/− littermates 
(95 ± 34 copies/cell; Whitney–Mann test: P < 0.0001), and similar to 
that of untreated wild-type livers (1402 ± 192; P = 0.90; Figure 2c). 
Intriguingly, the AAV-treated Mpv17+/− mice had slightly increased 
levels of mtDNA as well (1857 ± 144) compared to untreated litter-
mates (P < 0.0001; Figure 2c). Notably, an AAV expressing hMPV17 
tagged with a HA epitope, was neither able to enter the complex 
(Supplementary Figure S2a) nor to complement the mtDNA deple-
tion (Supplementary Figure S2b) in spite of high viral content in 
liver (Supplementary Figure S2c), suggesting that the HA epitope 
Figure 1 Characterization of the Mpv17-containing macromolecu-
lar complex. Liver mitochondria from (a) Mpv17+/− and (b) Mpv17−/− 
mice were analyzed by 2D BNGE. The blots were immunostained with 
an αMPV17 antibody; the filter was then stripped and restained with 
an αCore 1 antibody to determine the molecular weight of the com-
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hampers the function of MPV17, possibly by interfering with the for-
mation of the supramolecular complex, which appears as necessary 
for mtDNA maintenance. As expected, the mtDNA copy number 
in skeletal muscle was similar in treated versus untreated Mpv17−/− 
individuals (data not shown). The increase in mtDNA copy number 
in AAV-treated versus untreated Mpv17−/− livers, was paralleled by 
an increase in mtDNA-encoded transcripts (COI, COII, ND5, ND6, 
and CYTB), and in the enzymatic activities of complexes I, III, and 
IV (Figure 2f,g). Mitochondrial respiratory chain (MRC) activities 
were not increased in mice treated with hMPV17-HA-recombinant 
AAV vectors (Supplementary Figure S2d), and in fact transaminase 
levels were as high as those found in untreated naive Mpv17−/− litter-
mates (Supplementary Figure S2e).
KD induces severe cirrhosis in Mpv17−/− mice
KD supplies ≈80% of the energy from fat. Although KD has been 
suggested to induce mitochondrial biogenesis in skeletal mus-
cle,23 it seems to act detrimentally in OXPHOS-defective mouse 
models unable to consume the excess of NADH derived from fat 
metabolism.24 We investigated the effects of KD administered for 
2 months to 2-month-old groups of Mpv17−/− and Mpv17+/− mice 
(n = 4 individuals each). Both Mpv17−/− and Mpv17+/− KD-treated 
animals showed initial weight loss, which was progressively recov-
ered by Mpv17+/− but not Mpv17−/− individuals (Supplementary 
Figure S3a). After 2 months, KD-treated mice showed marked 
increase of plasma alanine aminotransferase and aspartate ami-
notransferase levels, which was much higher in the Mpv17−/− than 
Figure 2 Molecular and clinical characterization of AAV2/8-TBG-h.MPV17-treated mice. A single retroorbital injection of 4 × 1012 vg/kg was 
performed in 2-month-old Mpv17+/− and Mpv17−/− mice. (a) Analysis of AST and ALT plasma levels in mice before and after AAV administration. The 
Asterisks (*) indicate significance (P), calculated by either the Wilcoxon test to compare mice pre- and post-AAV treatment, or the Mann–Whitney test 
to compare different groups of animals: *P < 0.05; ***P < 0.0001. (b) Viral DNA content in livers from Mpv17+/− and Mpv17−/− mice. No amplifica-
tion was obtained in AAV-untreated mice. Color codes: solid blue: untreated Mpv17+/−; blue outline: AAV-treated Mpv17+/−; solid red: Mpv17−/−; red 
outline: AAV-treated Mpv17−/−. Bars indicate the standard deviation (SD). (c) Mitochondrial DNA (MtDNA) content in livers from AAV-treated and 
untreated Mpv17+/− and Mpv17−/− mice. Note that mtDNA content in AAV-treated animals is comparable to that of naive Mpv17+/− animals, and that 
a slight, but significant, increase is also present in the AAV-treated versus untreated controls. Color codes: solid blue: untreated Mpv17+/−; blue outline: 
AAV-treated Mpv17+/−; solid red: Mpv17−/−; red outline: AAV-treated Mpv17−/−. Bars indicate the SD. Asterisks (*) indicate significance (P) calculated 
by the Mann–Whitney test: *P < 0.05; **P < 0.01; ***P < 0.0001. (d) Western blot analysis of the h.MPV17 protein: the amount detected in isolated 
liver mitochondria from three AAV-treated Mpv17−/− mice is higher than that detected in Mpv17-/+ littermates, whereas the protein is absent in a 
mitochondrial sample from a Mpv17−/− naive individual. (e) Two-dimensional blue native gel electrophoresis on liver mitochondria from AAV-treated 
Mpv17−/− mice. Note that the spot has a molecular weight similar to the CIII2+CIV supercomplex, as determined by staining with an αCore1 antibody. 
(f) mRNA expression analysis. Note that AAV-treated Mpv17−/− mice show normal levels of transcripts. All values are normalized to the untreated 
control. Color codes: solid blue: untreated Mpv17+/−; blue outline: AAV-treated Mpv17+/−; solid red: Mpv17−/−; red outline: AAV-treated Mpv17−/−. Bars 
indicate the SD. Asterisks (*) indicate significance (P) calculated by the Mann–Whitney test: *P < 0.05; ***P < 0.0001. (g) Mitochondrial respiratory 
chain activities in treated versus untreated Mpv17+/− and Mpv17−/− mice. CI, CIII, and CIV activities are normalized in AAV-treated Mpv17−/− animals. 
Note that CS activity, which is increased in Mpv17−/− mice, is normal in the AAV-treated group. Color codes: solid blue: untreated Mpv17+/−; blue 
outline: AAV-treated Mpv17+/−; solid red: Mpv17−/−; red outline: AAV-treated Mpv17−/−. Bars indicate the SD. Asterisks (*) indicate significance (P) cal-
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in the Mpv17+/− group (Supplementary Figure S3b). At necros-
copy, the Mpv17−/− livers were markedly enlarged and yellowish 
(Supplementary Figure S3c). Histologic examination revealed 
diffuse micro- and macrovacuolar steatosis, hepatocellular necro-
sis with inflammatory infiltrates, and lipogranulomas. In addition, 
picrosirius red, which selectively stains collagen fibers, showed 
fibrous septa surrounding nodules of regenerating hepatocytes, 
consistent with cirrhosis (Figure 3a,b). Contrariwise, Mpv17+/− liv-
ers displayed only a mild, albeit variable, micro- and macrovacuo-
lar steatosis, and perisinusoidal collagen deposition (Figure 3c,d), 
as expected by prolonged exposure to a high-fat diet. The mtDNA 
content was unchanged in both KD-fed genotypes compared to 
standard diet (SD)-fed littermates, indicating that KD failed to 
induce mitochondrial biogenesis in liver (Supplementary Figure 
S4a), as confirmed by histochemical staining for cytochrome c 
oxidase (Supplementary Figure S4b). Indeed, transcript analysis 
showed a reduction of some MRC subunits in KD- versus SD-fed 
mice (Supplementary Figure S4c,d). Massive steatosis prevented 
us to perform spectrophotometric assays of MRC activities in liver 
homogenates.
AAV-mediated Mpv17 expression corrects liver 
damage of KD
We next investigated whether treatment by AAV2/8-hMPV17 
was able to prevent and/or correct the severe liver derangement 
induced in Mpv17−/− mice by KD. In a first protocol, aiming at 
preventing damage, KD administration for 2 months was started 3 
weeks after the injection of 4 × 1012 (n = 4) or 4 × 1013 (n = 3) vg/kg 
AAV2/8-hMPV17 into 2-month-old Mpv17+/− and Mpv17−/− mice. 
Here, we show the data referred to the higher viral dose, but similar 
results were also obtained using the lower dose (Supplementary 
Figure S5). Body weights were monitored throughout the experi-
ment, and hepatic enzyme levels were measured at the end of 
the treatment. As mentioned before, untreated Mpv17−/− mice 
showed progressive loss of body weight, whereas AAV-treated 
Mpv17−/− individuals recovered their starting weight after initial 
loss, and gained weight over time with a trend similar to that of 
AAV-treated and untreated Mpv17+/− animals (Supplementary 
Figure S6a). In contrast to untreated KD-fed Mpv17−/− mice, 
AAV-treated KD-fed Mpv17−/− mice showed plasmatic levels of 
hepatic enzymes similar to those of control littermates in KD 
(Supplementary Figure S6b). Livers from KD-fed AAV-treated 
Mpv17−/− animals were significantly less enlarged (9.9 ± 2.6 versus 
7.0 ± 1.0; Mann–Whitney test: P < 0.01; Supplementary Figure 
S6c), and remarkably less damaged upon histological examina-
tion than those from untreated Mpv17−/− littermates (Figure 4). 
Eventually, while AAV-untreated Mpv17−/− individuals invariably 
developed overt cirrhosis and necrosis by 2 months of KD, AAV-
treated Mpv17−/− animals showed only variable degrees of steatosis 
and some inflammatory infiltrates, comparable to those of control 
animals exposed to the same diet (Figure 4). These results clearly 
indicate that AAV2/8-hMPV17 treatment prevents KD-induced 
liver damage in Mpv17−/− mice.
We observed that the viral DNA content was much lower 
in KD-fed than in SD-fed livers (1.2 ± 0.2 versus 12.8 ± 2.3 in 
Mpv17+/−, P < 0.05; 0.4 ± 0.3 versus 14.8 ± 1.0 copies/cell in 
Mpv17−/−, P < 0.05; Figure 5a), suggesting that KD induced strong 
dilution of viral DNA. Since the DNA of recombinant AAV vec-
tors remains episomal25 and is replication-defective, a possible 
explanation for this phenomenon is increased cell proliferation. 
Figure 3 Histological analysis of livers from ketogenic diet (KD)-fed 
mice. Hematoxylin and eosin (a and c) and picrosirius red (b and d) 
staining in KD-fed Mpv17−/− and Mpv17+/− livers. See text for details. 






Figure 4 Histological analysis of livers from ketogenic diet (KD)-fed 
mice pretreated with AAV. A single retroorbital injection of 4 × 1013 vg/
kg was performed in 2 months old Mpv17+/− and Mpv17−/− mice. KD was 
started 3 weeks later. (a–d) Hematoxylin and eosin. (e–h) Picrosirius red 
staining. (a–e) Untreated Mpv17+/−. (b–f) AAV-treated Mpv17+/−. (c–g) 
Untreated Mpv17−/−. (d–h) AAV-treated Mpv17−/−. See text for details. 
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To confirm this hypothesis, we performed quantitative analysis of 
proliferating versus nonproliferating hepatocytes by measuring 
proliferating cell nuclear antigen, a marker of cell proliferation.26 
The nuclear staining index for proliferating cell nuclear antigen 
was 18.2 ± 13.6% in SD versus 74.2 ± 7.7% in KD in Mpv17+/− 
and 20.9 ± 15.1% in SD versus 81.7 ± 12.5 in KD in Mpv17−/− 
mice (Student t-test: P < 0.005 for both groups; Supplementary 
Figure S7a). Similar results were obtained in AAV-treated mice 
(Supplementary Figure S7b). This result highlights the effect 
of KD in promoting hepatocyte proliferation in mouse liver 
and may explain the decrease of viral content observed during 
the KD treatment. Nevertheless, the mtDNA content increased 
from 49 ± 8 copies/cell in naive Mpv17−/− to 576 ± 211 copies/cell 
in AAV-treated Mpv17−/− littermates (Figure 5b). This increase 
was paralleled by robust expression of mtDNA transcripts, 
becoming quantitatively comparable to that of untreated KD-fed 
Mpv17+/−littermates (Figure 5c), and led to significant recovery of 
cytochrome c oxidase histochemical activity (Figure 5d).
In a second protocol, aiming at correcting damage, we tested 
whether AAV-based hMPV17 gene replacement therapy can stop 
or reverse an already ongoing liver derangement, as typically 
found in patients. We first KD-fed for 1 month two groups of 
2-month-old Mpv17−/−and Mpv17+/−mice. This treatment caused 
liver damage, as clearly indicated by increased hepatic-enzyme 
levels in plasma of both groups (Supplementary Figure S8a). We 
then administered 4 × 1013 vg/kg of AAV-hMPV17 to both groups 
of animals, while KD was continued for one additional month 
before sacrifice, so that this group of mice was overall exposed 
to KD as long as the first group. Livers from Mpv17−/− animals 
showed a statistically nonsignificant trend toward reduced hepa-
tomegaly compared to untreated littermates, whereas livers from 
Mpv17+/− mice were unaffected (Supplementary Figure S8b).
Again, the livers from Mpv17−/− mice were protected from 
developing extensive KD-induced liver damage, showing mod-
erate hepatocyte steatosis, in the absence of necrosis and fibrosis 
(Figure 6a,b), while livers from Mpv17+/− exposed to this protocol 
displayed only mild and focal steatosis (Figure 6c,d). Viral DNA 
quantification showed 5.6 ± 3.1 vg/cell in Mpv17−/−and 5.0 ± 2.5 
vg/cell in Mpv17+/− mice (Figure 7a), leading to high levels of 
MPV17 mRNA in both Mpv17−/−and Mpv17+/−livers (Figure 7b). 
The mtDNA copy number was significantly increased in AAV-
treated versus untreated Mpv17−/− individuals (501 ± 263 versus 
49 ± 8; Mann–Whitney test: P < 0.01) although remained lower 
than in treated (1387 ± 331 copies/cell) and untreated (1384 ± 194 
Figure 5 Molecular and biochemical characterization of ketogenic diet (KD)-fed mice pretreated with AAV. (a) Viral DNA content in livers from 
AAV-treated Mpv17+/− and Mpv17−/− mice in standard diet (SD) versus KD. Blue stripes: AAV-treated Mpv17+/− mice in SD; blue outline: AAV-treated 
Mpv17+/− mice in KD; red stripes: AAV-treated Mpv17−/− mice in SD; red outline: AAV-treated Mpv17−/− mice in KD. Bars indicate the standard deviation 
(SD). (b) Mitochondrial DNA (MtDNA) analysis in AAV-treated versus untreated, KD-fed mice. Note that mtDNA content in AAV-treated Mpv17−/− is 
higher than in untreated littermates, but remains lower than in control littermates. (c) Mitochondrial transcripts analysis in AAV-treated versus untreated, 
KD-fed mice. All values are normalized to the KD-fed untreated controls. (d) Cytochrome c oxidase histochemical staining. In b and c, the asterisks (*) 
indicate significance (P) calculated by the Mann–Whitney test for independent samples: *P < 0.05; ***P < 0.0001. Color codes: solid blue: untreated 
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copies/cell) Mpv17+/−littermates (Figure 7c). In parallel, mito-
chondrial transcripts were significantly increased in the Mpv17−/− 
livers, up to levels comparable to KD-fed control littermates 
(Figure 7b), and cytochrome c oxidase histochemical activity was 
increased as well (Figure  7d). Nevertheless, the overall clinical 
conditions were clearly worse in post-KD AAV-treated than in 
pre-KD AAV–treated Mpv17−/− mice. The hepatic enzyme levels 
increased, whereas the body weight decreased (Supplementary 
Figure S8c,d), suggesting that our “late” AAV treatment can pos-
sibly slow the evolution of preexisting liver damage, but is unable 
to reverse the downhill clinical progression of the disease.
DISCUSSION
We here provide novel information on the connection between 
MPV17 and mtDNA maintenance, although the complete eluci-
dation of the physiological role of this elusive, medically relevant, 
and biologically intriguing protein is still missing. First, we have 
demonstrated that, like the yeast ortholog SYM1, mammalian 
MPV17 forms a high molecular weight complex in both cell cul-
tures and mouse tissues. By reconstitution into lipid bilayers, Sym1 
has recently been shown to aggregate as a high molecular com-
plex to form a functional pore possibly a cation channel.27 Similar 
to mitochondrial carrier proteins, both Mpv17 and SYM1 are 
imported into the inner mitochondrial membrane via the TIM23 
complex without cleavage of a leader peptide. A channel activity 
has not been (yet) demonstrated for the mammalian Mpv17, but 
we have shown here that Mpv17 participates in a high molecular 
weight complex necessary for its function, since variants that fail 
Figure 7 Molecular and biochemical characterization of livers from AAV posttreated, ketogenic diet (KD)-fed mice. (a) Viral DNA content in liv-
ers. (b) Mitochondrial DNA (MtDNA) analysis. Note that mtDNA content in AAV-treated Mpv17−/− is higher than in untreated littermates, but remains 
lower than in control littermates. (c) Mitochondrial transcripts analysis. (d) Cytochrome c oxidase histochemical staining in b and c. The asterisks (*) 
indicate significance (P) calculated by the Mann–Whitney test for independent samples; **P < 0.001; ***P < 0.001. Color codes: solid blue: untreated 



























































Figure 6 Histological analysis of livers from AAV posttreated, 
 ketogenic diet (KD)-fed mice. A single retroorbital injection of 4 × 1013 
vg/kg was performed in two-month old Mpv17+/− and Mpv17−/− mice one 
month after starting KD. (a and c) Hematoxylin and eosin and (b and d) 
picrosirius red staining in AAV posttreated Mpv17−/− and Mpv17+/− livers. 
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to be incorporated do not rescue the liver phenotype of Mpv17−/− 
mice, including mtDNA depletion.
A second goal of our work consisted in the development of 
therapeutic strategies for liver-specific MDS. Although many 
mitochondrial abnormalities cause multisystem disorders, some 
affect only or predominantly a single organ, being thus ame-
nable to treatment by tissue-specific gene replacement. Most 
of the MPV17 mutant cases are characterized by early onset, 
often fatal liver failure, associated with profound tissue-specific 
mtDNA depletion, whereas other tissues are relatively (e.g., skel-
etal muscle) or completely (e.g., heart) spared. We used recom-
binant AAV vectors to target the therapeutic gene to the liver, 
because this approach is relatively safe, noninvasive, and trans-
latable to humans, we clearly showed that AAV-mediated expres-
sion of human MPV17 in Mpv17−/− mouse livers can correct the 
molecular phenotype, i.e., severe mtDNA depletion, in standard 
conditions, thus normalizing the MRC defects. We then showed 
that KD causes Mpv17−/− mice to rapidly develop severe hepato-
megaly and macrovacuolar steatosis, which evolves into cirrhosis 
and overt liver failure within 2 months. By contrast, Mpv17+/− lit-
termates exposed to the same diet displayed only mild steatosis, 
mostly of the microvacuolar type. Administration of AAV2/8-
hMPV17 before starting KD effectively protected Mpv17−/− mice 
from liver derangement.
Partial protection from KD-induced liver failure was also 
obtained in mice exposed to KD before AAV treatment, that is 
when liver damage was already ongoing, as indicated by elevated 
plasma levels of hepatic enzymes. However, in this case, AAV 
treatment was able to halt the progression of the disease, but 
not to revert already established liver damage. This result is in 
agreement with the evidence that the AAV1 serotype is able to 
efficiently transduce both normal and cirrhotic livers,28 with no 
significant dilution of the viral load over time.
We propose AAV2/8-based therapy as a realistic strategy to 
prevent liver failure in patients with mutations in MPV17 and 
eventually in other forms of liver MDS. AAV2/8 serotype can 
remain for a long time in the liver of mice,29–31 cats,32 and humans,33 
with no significant side effects. While targeting of AAV-mediated 
therapeutic protein is still challenging for large-size tissues such 
as skeletal muscle or impermeable organs such as the brain, this 
approach is becoming a realistic option for gene conditions affect-
ing a single, compliant organ, such as the liver in case of hepatic 
MDS, for proteins that are secreted by a targetable organ, such 
as the liver again for factor IX, the circulating enzyme missing 
in hemophilia B,33 or in disorders that can be effectively cured 
by using liver to clear the bloodstream from toxic substances by 
making liver competent for clearing the bloodstream from toxic 
compounds. The latter strategy has proven successful for ethyl-
malonic encephalopathy, a mitochondrial disease due to the accu-
mulation of toxic free sulphide22 and can in principle be applied to 
mitochondrial neurogastrointestinal encephalomyopathy, due to 
accumulation of thymidine to toxic levels in plasma and tissues.
MATERIALS AND METHODS
Construction of AAV2/8 vectors. AAV2/8-TBG-h.MPV17 and AAV2/8-
TBG-h.MPV17HA vectors were produced by the AAV Vector Core of 
the Telethon Institute of Genetics and Medicine (Naples, Italy) by triple 
transfection of 293 cells and purified by CsCl gradients.34 Physical titers 
of the viral preparations (genome copies per ml) were determined by real-
time PCR35 (Applied Biosystems, Foster City, CA) and dot-blot analysis.
Genomic DNA extraction, PCR, and quantitative PCR. Total DNA was 
extracted from frozen tissues using the Maxwell apparatus (Promega, 
Madison, WI) following the instructions of the manufacturer. AAV-derived 
DNA was detected by standard PCR amplification using primer pairs spe-
cific to the hMPV17 gene. SYBR-GREEN–based real-time quantitative PCR 
was carried out for mtDNA and AAV-copy number analysis as previously 
described10,22; the RNAseP gene was used as a reference. Total RNA was 
extracted from liquid nitrogen snap frozen liver by Total RNA Mini Kit (tis-
sue), according to the manufacturer’s instructions (Geneaid, Taipei, Taiwan). 
Of total RNA, 2 μg was treated with Rnase-free DNase and retrotranscribed 
using the GoTaq 2-Step RT-qPCR System (Promega). Approximately 25 ng 
of cDNA was used for real-time PCR assay using primers specific for amplifi-
cation of several genes.36 Oligonucleotide sequences are available on request.
Biochemical analysis of MRC complexes. Liver samples stored in liquid 
nitrogen were homogenized in 10 mmol/l phosphate buffer (pH 7.4), and 
the spectrophotometric activity of cI, cII, cIII, and cIV, as well as citrate 
synthase, was measured as described.37
Morphological analysis. Histochemical analyses were performed as 
described.38 Hematoxylin and eosin and picrosirius red staining were per-
formed according to standard protocols. Livers were formalin fixed and 
paraffin embedded. Consecutive sections (5–6 μm thick) were stained 
with hematoxylin and eosin and picrosirius red for histologic examina-
tion. Immunostaining with antiproliferating cell nuclear antigen monoclo-
nal antibodies (Abcam, Cambridge, UK; dilution 1:6,000) was performed 
for quantitative evaluation of proliferating hepatocytes. Two-hundred cells 
per slide were manually counted in four high-power fields (original magni-
fication: ×40), and the number of proliferating hepatocytes (in all cell cycle 
stages) was expressed as a ratio over the total cell number.
Immunoblotting. Ten percent weight per volume homogenates in 10 
mmol/l phosphate buffer pH 7.4 were prepared from liver and centrifuged 
at 800g for 10 minutes to eliminate cellular debris. Total protein extracts 
were run through a 12% sodium dodecyl sulfate–polyacrylamide gel (40 
μg/sample) and electroblotted onto nitrocellulose filters. The filters were 
immunostained with specific antibodies against MPV17 (Proteintech, 
Manchester, UK), Core1, and the 70 kDa subunit of succinate dehydro-
genase (Molecular Probes; Invitrogen, Paisley, UK), and protein bands 
were visualized using the ECL chemioluminscence kit (Amersham, Milan, 
Italy). Twenty microgram of proteins from isolated liver mitochondria39 
were run on a 12% sodium dodecyl sulfate–polyacrylamide gel.
BNGE was performed in isolated liver mitochondria as described.40 
Fifteen microliters of sample were run through a 5–13% nondenaturating 
gradient (1D-BNGE). For denaturing two-dimensional BNGE 
electrophoresis, the one-dimensional BNGE lane was excised, treated 
for 1 hour at room temperature (20 °C) with 1% sodium dodecyl sulfate 
and 1% β-mercaptoethanol and then run through a 16.5% tricine-sodium 
dodecyl sulfate–polyacrylamide gel using a 10% spacer gel.
Analysis of body fluids. aspartate aminotransferase and alanine amino-
transferase were determined in blood samples by standard methods.
Experimental ethics policy. Animal studies were approved by the Ethics 
Committee of the Foundation ‘Carlo Besta’ Neurological Institute, in 
accordance with the guidelines of the Italian Ministry of Health. The 
use and care of animals followed the Italian Law D.L. 116/1992 and the 
EU directive 86/609/CEE. The mice were kept on a C57Bl6/129Sv mixed 
background, and wild-type littermates were used as controls. Standard 
food and water were given ad libitum. KD was administered for 2 months 
(SSNIFF, Germany) ad libitum. Body weight and food consumption were 
monitored twice a week.
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Figure S1. Alignment of eukaryotic Mpv17 orthologues.
Figure S2. AAV-mediated expression of hMPV17-HA in Mpv17−/− mice.
Figure S3. Effects of KD on Mpv17−/− and control littermates.
Figure S4. KD does not induce mitochondrial biogenesis in liver.
Figure S5. AAV2/8-hMPV17 4 × 1012 vg/kg partially rescues KD-
induced liver damage inMpv17−/− mice.
Figure S6. AAV2/8-hMPV17 4 × 1013 vg/kg rescues KD-induced liver 
damage in Mpv17−/− mice.
Figure S7. Effect of KD on hepatocytes proliferation.
Figure S8. Effects of administration of AAV-hMPV17 in mice pretreat-
ed with KD.
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